{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T21:12:41Z","timestamp":1794690761886,"version":"4.9.1"},"reference-count":15,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1136\/ard.2008.102053","type":"journal-article","created":{"date-parts":[[2009,1,16]],"date-time":"2009-01-16T01:25:11Z","timestamp":1232069111000},"page":"48-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":618,"title":["Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment"],"prefix":"10.1016","volume":"69","author":[{"given":"L C","family":"Coates","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Fransen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P S","family":"Helliwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2008.102053_bib1","first-page":"127","article-title":"Psoriatic arthritis (PSA)\u2014an analysis of 220 patients.","volume":"62","author":"Gladman","year":"1987","journal-title":"Q J Med"},{"key":"10.1136\/ard.2008.102053_bib2","first-page":"1417","article-title":"Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines.","volume":"33","author":"Kavanaugh","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2008.102053_bib3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","article-title":"Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.","volume":"364","author":"Grigor","year":"2004","journal-title":"Lancet"},{"key":"10.1136\/ard.2008.102053_bib4","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1002\/art.21405","article-title":"Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.","volume":"52","author":"Goekoop-Ruiterman","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.102053_bib5","unstructured":"Kavanaugh A, Fransen J,. Defining remission in psoriatic arthritis. Clin Exp Rheumatol 2006;24(6 Suppl 43):S-83\u20137."},{"key":"10.1136\/ard.2008.102053_bib6","first-page":"2016","article-title":"Minimal disease activity for rheumatoid arthritis: a preliminary definition.","volume":"32","author":"Wells","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2008.102053_bib7","first-page":"1167","article-title":"Consensus on a core set of domains for psoriatic arthritis.","volume":"34","author":"Gladman","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2008.102053_bib8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/art.20421","article-title":"Could the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) be a valid measure of disease activity in patients with psoriatic arthritis?","volume":"51","author":"Taylor","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.102053_bib9","first-page":"214","article-title":"GRAPPA\u2014Group for Research and Assessment of Psoriasis and Psoriatic Arthritis, Stockholm, May\/June 2006.","volume":"34","author":"Helliwell","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2008.102053_bib10","first-page":"2409","article-title":"Progression in psoriatic arthritis: role of time varying clinical indicators.","volume":"26","author":"Gladman","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2008.102053_bib11","first-page":"675","article-title":"Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model.","volume":"22","author":"Gladman","year":"1995","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2008.102053_bib12","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.102053_bib13","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression.","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.102053_bib14","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/ard.42.6.644","article-title":"Clinical judgment in rheumatoid arthritis. I. Rheumatologists' opinions and the development of \u2018paper patients\u2019.","volume":"42","author":"Kirwan","year":"1983","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2008.102053_bib15","first-page":"198","article-title":"The OMERACT filter for Outcome Measures in Rheumatology.","volume":"25","author":"Boers","year":"1998","journal-title":"J Rheumatol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724196550?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724196550?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2008.102053","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T14:14:10Z","timestamp":1736086450000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724196550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S0003496724196550"],"URL":"https:\/\/doi.org\/10.1136\/ard.2008.102053","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2008.102053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Published by Elsevier Inc. Publishing Group Ltd and European League Against Rheumatism. All rights reserved. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}